4 results
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Primary objective:* Demonstrating clinical superiority of MOD-4023 compared to placebo in terms of reduction of fat mass (FM) in adults persons with GHDSecondary objectives:* Determining the efficacy of MOD-4023 compared to placebo in other body…
efficacy of lanreotide LAR in controling total liver volume in patients with hepatic cysts as a result of ADPKD or PCLD
Investigation of the impact of a treatment consisting of inhalation antibiotics and prolonged oral antibiotic course during a bacterial exacerbation on the prevention of further exacerbations.